Tag

Jp Morgan Healthcare Conference

All articles tagged with #jp morgan healthcare conference

business9 hours ago

Pharma Leaders Push Back Against RFK Jr.'s Vaccine Attacks

At the JPMorgan Healthcare Conference, Pfizer CEO Albert Bourla and other pharma leaders publicly rebuked RFK Jr.’s anti-vaccine campaign, calling it politically driven and scientifically unfounded as Kennedy overhauls the childhood vaccine schedule. Executives warned the rhetoric could spill into other vaccines, raise litigation risks, and fuel misinformation, while emphasizing the need for evidence-based policy and maintaining vaccine confidence during a challenging flu season and in the run-up to elections.

healthcare-conference2 years ago

"Key Highlights from J.P. Morgan Healthcare Conference 2024"

The 2024 J.P. Morgan Healthcare Conference featured updates from industry leaders including Medtronic, Abbott, Shockwave Medical, Dexcom, and Johnson & Johnson MedTech. Medtronic focused on restoring earnings power and highlighted growth opportunities in cardiac ablation, diabetes, and structural heart, while also announcing the creation of the Medtronic AI Center of Excellence. Abbott touted the success of its FreeStyle Libre continuous glucose monitoring device and its plans for further growth, while Shockwave Medical emphasized product launches and global expansion efforts. Dexcom unveiled its new Stelo sensor designed for people with type 2 diabetes, and Johnson & Johnson MedTech highlighted its growth through M&A activities and recent developments in surgical robotics and pulsed field ablation.

biotech-industry2 years ago

"Highlights from JPM 2024: Gene Editing, Biotech Breakthroughs, and More"

The biotech industry in San Francisco is experiencing a surge of positive energy and optimism, attributed to a recent increase in deals and a change in sentiment. The abundance of sunlight and a surge of deals in December have contributed to a more positive outlook for the industry, with many noting a change in tenor and projecting a positive future moving forward.

businesshealthcare-conference2 years ago

"Highlights from J.P. Morgan Healthcare Conference 2024"

The J.P. Morgan Healthcare Conference, a hallmark event in its 42nd year, has returned to San Francisco's Union Square, drawing thousands of attendees and major industry players. The event is expected to bring significant economic impact to the city, with last year's in-person conference generating about $86 million. Keynote speakers include former British Prime Minister Tony Blair and JPMorgan Chase & Co. CEO Jamie Dimon, while major announcements and deals in the healthcare industry have already been made. The conference is seen as a boost to the local economy and a positive start to the new year for San Francisco's commercial core.

healthcare-and-biotech2 years ago

"J.P. Morgan Healthcare Conference: Medtech Updates and Biotech M&A Frenzy"

The upcoming J.P. Morgan Healthcare Conference in San Francisco is set to showcase the recent surge in biotech deal-making, the growing interest in weight-loss drugs, and the increasing prominence of artificial intelligence in the healthcare sector. With over 80,000 attendees expected, including representatives from leading drugmakers and financial firms, the event will feature discussions on the rise of M&A activity in pharma and biotech, the success of weight-loss drugs like GLP-1 receptor agonists, and the impact of AI on healthcare technology and distribution. Notable companies scheduled to present at the conference include Amgen, Eli Lilly, AbbVie, Moderna, Johnson & Johnson, and various health equipment and healthcare companies.

business2 years ago

"Biotech Rout Persists: Hospitals Project Optimism at J.P. Morgan Healthcare Conference"

The 42nd Annual J.P. Morgan Healthcare Conference in San Francisco brings hope to the biotech industry as the Federal Reserve halts interest rate hikes and deal-making increases, leading to a recovery in biotech stock prices. Major drug development successes, including medications for weight and diabetes control and the first FDA-approved medicine using CRISPR-Cas9, have bolstered industry optimism. Recent multibillion-dollar acquisitions of Massachusetts drug firms by pharmaceutical giants also signal a positive outlook, although companies remain cautious and continue to save money amidst ongoing challenges.